U.S. markets closed
  • S&P Futures

    3,927.50
    +5.00 (+0.13%)
     
  • Dow Futures

    31,996.00
    +80.00 (+0.25%)
     
  • Nasdaq Futures

    13,304.75
    +2.75 (+0.02%)
     
  • Russell 2000 Futures

    2,296.90
    +11.80 (+0.52%)
     
  • Crude Oil

    63.39
    +0.17 (+0.27%)
     
  • Gold

    1,794.80
    -3.10 (-0.17%)
     
  • Silver

    28.06
    +0.20 (+0.72%)
     
  • EUR/USD

    1.2168
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.3890
    +0.0270 (+1.98%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4141
    -0.0000 (-0.00%)
     
  • USD/JPY

    106.0050
    +0.1230 (+0.12%)
     
  • BTC-USD

    50,348.92
    +378.04 (+0.76%)
     
  • CMC Crypto 200

    1,004.03
    -10.89 (-1.07%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,156.48
    +484.78 (+1.63%)
     

How Much Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

If you want to know who really controls Intellia Therapeutics, Inc. (NASDAQ:NTLA), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that have been privatized tend to have low insider ownership.

Intellia Therapeutics isn't enormous, but it's not particularly small either. It has a market capitalization of US$1.2b, which means it would generally expect to see some institutions on the share registry. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholder can tell us about Intellia Therapeutics.

Check out our latest analysis for Intellia Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Intellia Therapeutics?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Intellia Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Intellia Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. Hedge funds don't have many shares in Intellia Therapeutics. Our data shows that ARK Investment Management LLC is the largest shareholder with 17% of shares outstanding. Nikko Asset Management Co., Ltd. is the second largest shareholder owning 11% of common stock, and Novartis AG holds about 7.4% of the company stock. In addition, we found that John Leonard, the CEO has 0.0089507 of the shares allocated to his name

On further inspection, we found that more than half the company's shares are owned by the top 6 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Intellia Therapeutics

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board; and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board, themselves.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

I can report that insiders do own shares in Intellia Therapeutics, Inc.. This is a big company, so it is good to see this level of alignment. Insiders own US$17m worth of shares (at current prices). Most would say this shows alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.

General Public Ownership

The general public, with a 21% stake in the company, will not easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Company Ownership

It seems that Private Companies own 3.1%, of the NTLA stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Public Company Ownership

We can see that public companies hold 7.4%, of the Intellia Therapeutics shares on issue. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 4 warning signs for Intellia Therapeutics (1 is a bit concerning!) that you should be aware of before investing here.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.